@article{article, title  = {{Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial}},

 publisher = {{Elsevier BV}},

 url = {{http://dx.doi.org/10.1016/s2665-9913(24)00065-1 }},

 year = {{2024}},

 month = {{5}},

 author = {{Goodyear CS and Patel A and Barnes E and Willicombe M and Siebert S and de Silva TI and Snowden JA and Lim SH and Bowden SJ and Billingham L and Richter A et al}},

 doi = {{10.1016/s2665-9913(24)00065-1}},

 volume = {{6}},

 journal = {{The Lancet Rheumatology}},

 issue = {{6}},

 pages = {{e339-e351}},

 note = {{Accessed on 2024/12/28}}}